

**GPR109B Antibody (N-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP19262a****Specification**

---

**GPR109B Antibody (N-term) Blocking Peptide - Product Information**

Primary Accession [P49019](#)

**GPR109B Antibody (N-term) Blocking Peptide - Additional Information**

**Gene ID** 8843

**Other Names**

Hydroxycarboxylic acid receptor 3, G-protein coupled receptor 109B, G-protein coupled receptor HM74, G-protein coupled receptor HM74B, Niacin receptor 2, Nicotinic acid receptor 2, HCAR3, GPR109B, HCA3, HM74B, NIACR2

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**GPR109B Antibody (N-term) Blocking Peptide - Protein Information**

**Name** HCAR3

**Synonyms** GPR109B, HCA3, HM74B, NIACR2

**Function**

Receptor for 3-OH-octanoid acid mediates a negative feedback regulation of adipocyte lipolysis to counteract prolipolytic influences under conditions of physiological or pathological increases in beta- oxidation rates. Acts as a low affinity receptor for nicotinic acid. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet.

**Cellular Location**

Cell membrane; Multi-pass membrane protein.

**Tissue Location**

Expression largely restricted to adipose tissue and spleen.

**GPR109B Antibody (N-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

#### **GPR109B Antibody (N-term) Blocking Peptide - Images**

#### **GPR109B Antibody (N-term) Blocking Peptide - Background**

Receptor for 3-OH-octanoid acid mediates a negative feedback regulation of adipocyte lipolysis to counteract prolipolytic influences under conditions of physiological or pathological increases in beta-oxidation rates. Acts as a low affinity receptor for nicotinic acid. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet.

#### **GPR109B Antibody (N-term) Blocking Peptide - References**

Bailey, S.D., et al. Diabetes Care (2010) In press :Mandrika, I., et al. Biochem. Biophys. Res. Commun. 395(2):281-287(2010)Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009)Jeninga, E.H., et al. J. Biol. Chem. 284(39):26385-26393(2009)Ahmed, K., et al. J. Biol. Chem. 284(33):21928-21933(2009)